Trial Profile
A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Daiichi Sankyo Inc
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 09 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 09 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.